Tesamorelin
Tesamorelin (stabilized GHRH(1-44) analog / GHRH receptor agonist peptide) · ≥98% (HPLC)
Characterized 44-residue GHRH-analog peptide (trans-3-hexenoyl-modified) supplied as a reference material for in-vitro receptor-signaling and analytical research. Not for human or veterinary use.
- Why researchers study it
- Studied in vitro as a structurally stabilized analog of growth-hormone-releasing hormone, used in laboratory investigations of GHRH receptor engagement, peptide-stability chemistry, and somatotrope-axis signaling models.
- Mechanism themes in research
- GHRH receptor (GHRHR) agonism in cell-based assaysGs/adenylyl-cyclase–cAMP signal-transduction cascadesN-terminal trans-3-hexenoyl modification conferring resistance to dipeptidyl-peptidase cleavageSomatotrope-axis (GH/IGF-1) signaling pathway models
- What the evidence does not establish
- Published references are in-vitro or pre-clinical and describe research context only. They do not establish safety, efficacy, or any outcome in humans or animals, and Helix makes no such claims.
- Quality markers
- ≥98% (HPLC)MS identityLot COACold-chain
Tesamorelin is a synthetic 44-amino-acid analog of human growth-hormone-releasing hormone (GHRH(1-44)) bearing a trans-3-hexenoyl modification on the N-terminal tyrosine. In research settings it is handled as a well-characterized peptide reference material (PubChem CID 16137828; CAS 218949-48-5; C₂₂₁H₃₆₆N₇₂O₆₇S; ~5135.86 g/mol) for in-vitro study of GHRH-receptor signaling, peptide-stability chemistry, and analytical identity. This listing is strictly Research Use Only and is not intended for any human or veterinary application.
Analytical identity
Supplied as a lyophilized powder characterized to ≥98% (HPLC). The molecule corresponds to PubChem CID 16137828 (CAS 218949-48-5), with molecular formula C₂₂₁H₃₆₆N₇₂O₆₇S and a reported monoisotopic/average molecular weight near 5135.86 g/mol. Identity and purity are typically confirmed by reversed-phase HPLC and mass spectrometry against the expected sequence and the N-terminal trans-3-hexenoyl modification.
Structure and sequence
The peptide reproduces the full 44-residue sequence of human GHRH(1-44) and carries a trans-3-hexenoyl (C6) acyl group anchored to the N-terminal tyrosine. This N-terminal modification is described in the literature as a structural feature that increases resistance to dipeptidyl-peptidase-mediated cleavage relative to the unmodified peptide, a property of interest in analog-stability and structure-activity chemistry studies.
| Full name | Tesamorelin (stabilized GHRH(1-44) analog / GHRH receptor agonist peptide) |
| Research theme | GH secretagogue |
| CAS number | 218949-48-5 |
| Molecular formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
| Molecular weight | 5135.86 g/mol |
| Purity | ≥98% (HPLC) |
| Physical form | Lyophilized powder |
| Storage | −20 °C, desiccated, protected from light |
Sequence
Reported research areas
- Peptide receptor pharmacology (GHRHR binding and signaling)
- Analog stability and structure-activity chemistry of GHRH peptides
- Endocrine-axis signaling pathway research in vitro
- Analytical method development and reference-standard characterization (HPLC/MS)
Credible sources
- PubChem CID 16137828 — Tesamorelin
- PubChem compound search — Tesamorelin
- PubMed literature — Tesamorelin
COA with every lot
Each Tesamorelin lot is characterized by reversed-phase HPLC for purity and by mass spectrometry for identity, then documented in a per-lot Certificate of Analysis. Unique lot numbers tie the vial back to its synthesis batch and analytical data.
- RP-HPLC purity result (≥98% (HPLC))
- Mass-spectrometry identity confirmation
- Appearance, molecular weight, and storage
- Lot number and testing status
Specimen Certificate of Analysis
| Product | Tesamorelin (reference) |
| Lot | HXR-2406-108 |
| Purity (RP-HPLC) | 98%+ |
| Identity (MS) | Confirmed · 5135.86 g/mol |
| Appearance | Lyophilized powder |
| Storage | −20 °C, desiccated |
Representative document. Each lot has its own COA — these are quality documents, not medical claims.